Beam Therapeutics (NASDAQ:BEAM – Get Free Report) and Onconetix (NASDAQ:ONCO – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.
Institutional & Insider Ownership
99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 23.9% of Onconetix shares are owned by institutional investors. 3.5% of Beam Therapeutics shares are owned by company insiders. Comparatively, 1.0% of Onconetix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Beam Therapeutics and Onconetix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Beam Therapeutics | -744.41% | -42.86% | -31.45% |
| Onconetix | -4,011.43% | -632.63% | -160.97% |
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Beam Therapeutics | $63.52 million | 44.12 | -$376.74 million | ($4.43) | -6.23 |
| Onconetix | $2.52 million | 0.87 | -$58.69 million | $10.89 | 0.13 |
Onconetix has lower revenue, but higher earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Beam Therapeutics and Onconetix, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Beam Therapeutics | 1 | 3 | 12 | 1 | 2.76 |
| Onconetix | 1 | 0 | 0 | 0 | 1.00 |
Beam Therapeutics currently has a consensus target price of $43.80, indicating a potential upside of 58.58%. Given Beam Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Beam Therapeutics is more favorable than Onconetix.
Risk and Volatility
Beam Therapeutics has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500. Comparatively, Onconetix has a beta of 3.45, suggesting that its stock price is 245% more volatile than the S&P 500.
Summary
Beam Therapeutics beats Onconetix on 11 of the 15 factors compared between the two stocks.
About Beam Therapeutics
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
About Onconetix
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
Receive News & Ratings for Beam Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beam Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
